Literature DB >> 12973933

Experimental study on the protective effect of puerarin to Parkinson disease.

Xueli Li1, Shenggang Sun, E'tang Tong.   

Abstract

The protective effect of puerarin on the Parkinson disease (PD) mice with decreased estrogen level was investigated in order to develop a new potential medicine as a substitute for estrogen for preventing and treating PD. By using immunohistochemical method of avidinbiotin peroxidase complex (ABC), the distribution of the cells positive for tyrosine hydroxylase (TH) and fibres in the substantia nigra of the mouse were observed. These mice were divided into three groups randomly: group A, normal-female-mouse models; group B containing three subgroups, B1 (normal saline), B2 (estrogen), B3 (puerarin); group C containing three sub groups, C1 (normal saline), C2 (estrogen), C3 (puerarin). By using TUNEL the numbers of apoptosis cells in every visual field was counted and the difference between the experimental group and control group was compared. The results showed the numbers of the cells positive for TH were more and the numbers of apoptosis cells were less in the normal-female-mouse models group than in the group of model made after ovariosteresis and the group of model made before ovariosteresis (P < 0.05), respectively. However, there was no significant difference, between the group given estrogen/puerarin and the controls, and between the group given estrogen and given puerarin. (P > 0.05). It was suggested that puerarin may have protective effect on the nigral neurons to PD. Moreover, the protective effect might serve as a surrogate of estrogen and be associated with the apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973933     DOI: 10.1007/BF02859940

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

Review 1.  Effects of estrogen on congnition mood, and degenerative brain diseases.

Authors:  J E Shepherd
Journal:  J Am Pharm Assoc (Wash)       Date:  2001 Mar-Apr

2.  Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons.

Authors:  H Sawada; M Ibi; T Kihara; M Urushitani; K Honda; M Nakanishi; A Akaike; S Shimohama
Journal:  FASEB J       Date:  2000-06       Impact factor: 5.191

Review 3.  Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons.

Authors:  H Sawada; S Shimohama
Journal:  Neurosci Biobehav Rev       Date:  2000-01       Impact factor: 8.989

4.  Soy isoflavone supplements antagonize reproductive behavior and estrogen receptor alpha- and beta-dependent gene expression in the brain.

Authors:  H B Patisaul; M Dindo; P L Whitten; L J Young
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

Review 5.  Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS.

Authors:  M Cyr; F Calon; M Morissette; M Grandbois; T Di Paolo; S Callier
Journal:  Curr Pharm Des       Date:  2000-08       Impact factor: 3.116

Review 6.  A review of the clinical effects of phytoestrogens.

Authors:  D C Knight; J A Eden
Journal:  Obstet Gynecol       Date:  1996-05       Impact factor: 7.661

7.  Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism.

Authors:  N Arai; K Misugi; Y Goshima; Y Misu
Journal:  Brain Res       Date:  1990-05-07       Impact factor: 3.252

8.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

9.  Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death.

Authors:  H Sawada; M Ibi; T Kihara; M Urushitani; A Akaike; S Shimohama
Journal:  J Neurosci Res       Date:  1998-12-01       Impact factor: 4.164

  9 in total
  5 in total

1.  Preventive effects of kudzu root on bone loss and cartilage degradation in ovariectomized rats [corrected].

Authors:  Yunyun Luo; Shuang Zheng; Yujia Ding; Yueqin Dai; Yi Zhou; Ruifeng Xiang; Anne C Bay-Jensen; Morten A Karsdal; Per Qvist; Qinlong Zheng
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 2.  The PI3K/AKT Pathway-The Potential Key Mechanisms of Traditional Chinese Medicine for Stroke.

Authors:  Chenyang Gu; Qiankun Zhang; Yajing Li; Rong Li; Jia Feng; Wanghao Chen; Waqas Ahmed; Ismatullah Soufiany; Shiying Huang; Jun Long; Lukui Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-31

3.  hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Authors:  Nian Xiong; Nuomin Li; Eden Martin; Jinlong Yu; Jie Li; Jing Liu; David Yue-Wei Lee; Ole Isacson; Jeffery Vance; Hong Qing; Tao Wang; Zhicheng Lin
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

4.  Puerarin exhibits greater distribution and longer retention time in neurons than astrocytes in a co-cultured system.

Authors:  Shu-Yong Wei; Jie Tong; Qiang Xue; Fang-Hong Shang; Yan-Jun Li; Yang Liu; Bin-Bin Feng; Xiao-Yu Xu
Journal:  Neural Regen Res       Date:  2015-04       Impact factor: 5.135

5.  Puerarin attenuates locomotor and cognitive deficits as well as hippocampal neuronal injury through the PI3K/Akt1/GSK-3β signaling pathway in an in vivo model of cerebral ischemia.

Authors:  Jinhao Tao; Yuehua Cui; Yu Duan; Nan Zhang; Congmin Wang; Fayong Zhang
Journal:  Oncotarget       Date:  2017-11-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.